Protocol Ledger

NCT03043651 · Phase III · TERMINATED

Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF

Interventional Phase III clinical trial protocol NCT03043651 sponsored by United Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-30 Enrollment: 48 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03043651
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)48 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03043651
Protocol FieldVerified Registry Value
NCT IdentifierNCT03043651
Consolidated Lead SponsorUnited Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment48 participants (ACTUAL)
Registered Start Date2018-01-30
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI